Oman Healthcare Market Research Report: Trends & Forecast (2026-2032)

By Healthcare Expenditure Type (Public Healthcare Expenditure, Private Healthcare Expenditure, Out-of-Pocket Expenditure), By Pharmaceutical Segment (Prescription Drugs, Over-the-Counter (OTC) Drugs,... ... ounter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologics & Biosimilars), By Therapeutic Area (Cardiovascular Diseases, Oncology, Diabetes, Respiratory Diseases, Neurology, Infectious Diseases, Others), By Medical Device Type (Diagnostic Imaging Devices, Patient Monitoring Devices, Surgical Equipment, In-vitro Diagnostics, Orthopedic Devices, Cardiovascular Devices, Others), By Technology Type (Artificial Intelligence in Healthcare, Telemedicine & Remote Monitoring, Electronic Health Records (EHR), Healthcare Analytics, Robotic Surgery, Wearables & Health Apps), By Healthcare Workforce (Physicians, Nurses, Dentists, Allied Health Professionals), By Insurance Type (Public Health Insurance, Private Health Insurance), By Disease Category (Chronic Diseases, Infectious Diseases, Mental Health Disorders), By End User (Hospitals, Clinics, Diagnostic Centers / Laboratories, Ambulatory Surgical Centers, Home Healthcare, Research Institutes, Pharmacies, Others) Read more

  • Healthcare
  • Mar 2026
  • 120
  • PDF, Excel, PPT

Oman Healthcare Market Report Key Takeaways:

  • The Oman Healthcare Market size was valued at USD 5.10 billion in 2025 and is projected to grow from USD 5.31 billion in 2026 to USD 6.74 billion by 2032, exhibiting a CAGR of 4.05% during the forecast period.
  • About 15% of patients in Oman in 2026 are affected by diabetes, highlighting its significant prevalence.
  • In 2026, around 10% of the total patients are affected by cardiovascular diseases.
  • Oman’s healthcare infrastructure includes 92 hospitals, over 1,100 outpatient care centers, and numerous rehabilitation and residential care facilities.

Market Insights & Analysis: Oman Healthcare Market (2026-32):

The Oman Healthcare Market size was valued at USD 5.10 billion in 2025 and is projected to grow from USD 5.31 billion in 2026 to USD 6.74 billion by 2032, exhibiting a CAGR of 4.05% during the forecast period, i.e., 2026-32.

The healthcare sector in Oman is undergoing a significant transformation as rising disease prevalence, expanding healthcare infrastructure, and growing investment in advanced medical technologies reshape healthcare delivery across the country.

Non-communicable diseases (NCDs) are a major driver of healthcare demand in Oman. According to the World Health Organization, conditions such as cardiovascular diseases, diabetes, cancer, and respiratory diseases account for 83% of deaths . In comparison, the Oman Ministry of Health reports that around 80% of deaths are linked to NCDs.

In addition to chronic diseases, Genetic disorders also contribute to healthcare demand in Oman. Sickle cell disease is among the most prevalent hereditary conditions, with 5.7–6% of the population carrying the gene and 0.2–0.46% affected , increasing the need for genetic screening, specialized diagnostics, and long-term treatment services.

According to the International Agency for Research on Cancer (GLOBOCAN), Oman recorded 13,006 five-year prevalent cancer cases, along with 4,045 new cases and 2,261 deaths, highlighting the country’s rising cancer burden and increasing demand for oncology services.

Healthcare infrastructure in Oman includes 92 hospitals and over 1,100 outpatient and primary healthcare centers . In 2023, the Oman Ministry of Health facilities performed 86,955+ surgeries. The system has 7,691 hospital beds, with a density of 14.9 beds per 10,000 population.

To further strengthen healthcare capacity, Oman is investing heavily in infrastructure expansion. The government is currently constructing 9 new hospitals that will add more than 1,660 beds nationwide. One of the largest projects is the 700-bed Sultan Qaboos Hospital in Salalah, which involves an investment of approximately USD 358.8 million and aims to improve access to specialized healthcare services in the southern region .

Alongside infrastructure expansion, Oman is also strengthening its pharmaceutical and medical manufacturing ecosystem. Government data indicates that the country currently hosts around 20 pharmaceutical and medical supply factories, including 7 pharmaceutical manufacturing plants, 2 raw-material facilities, and 11 medical supply production units .

Additional investment is also emerging within healthcare industrial zones. For instance, a USD 39 million pharmaceutical manufacturing facility is being developed in Khazaen Economic City to produce injectables, capsules, syrups, and topical medicines, supporting domestic drug production and supply chain resilience.

The government’s long-term healthcare development strategy is closely aligned with Oman Vision 2040, which focuses on building a modern and resilient healthcare system while encouraging private sector participation. Under this framework, the country aims to attract approximately USD 1.59 billion in healthcare investments by 2025, targeting hospital development, digital health platforms, and specialized treatment services.

Overall, the Oman healthcare market is positioned for steady growth as infrastructure expansion, rising chronic disease prevalence, and increasing investment in pharmaceutical manufacturing and medical technologies strengthen the national healthcare ecosystem. These structural developments are expected to enhance healthcare access, improve treatment capacity, and support the long-term evolution of the country’s healthcare sector.

Oman Healthcare Market Scope:

 Category  Segments
By Healthcare Expenditure Type (Public Healthcare Expenditure, Private Healthcare Expenditure, Out-of-Pocket Expenditure),
By Pharmaceutical Segment (Prescription Drugs, Over-the-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologics & Biosimilars),
By Therapeutic Area (Cardiovascular Diseases, Oncology, Diabetes, Respiratory Diseases, Neurology, Infectious Diseases, Others),
By Medical Device Type (Diagnostic Imaging Devices, Patient Monitoring Devices, Surgical Equipment, In-vitro Diagnostics, Orthopedic Devices, Cardiovascular Devices, Others),
By Technology Type (Artificial Intelligence in Healthcare, Telemedicine & Remote Monitoring, Electronic Health Records (EHR), Healthcare Analytics, Robotic Surgery, Wearables & Health Apps),
By Healthcare Workforce (Physicians, Nurses, Dentists, Allied Health Professionals),
By Insurance Type (Public Health Insurance, Private Health Insurance),
By Disease Category (Chronic Diseases, Infectious Diseases, Mental Health Disorders),
By End User (Hospitals, Clinics, Diagnostic Centers / Laboratories, Ambulatory Surgical Centers, Home Healthcare, Research Institutes, Pharmacies, Others)

Oman Healthcare Market Driver:

Rising Burden of Chronic Diseases

The rising prevalence of chronic and lifestyle diseases in Oman is increasing the demand for healthcare services. Urbanization, sedentary lifestyles, and dietary changes are driving metabolic and cardiovascular conditions, requiring long-term treatment, diagnostics, and continuous disease management.

One of the most critical public health challenges in Oman is the rising incidence of obesity and related metabolic disorders. National survey findings from the Oman Ministry of Health indicate that more than 60% of adults in the country are overweight or obese, while over 25% of the population is classified as obese . This growing obesity burden significantly increases the risk of other chronic diseases, including diabetes, cardiovascular disorders, and hypertension.

According to the 2025 National Survey of Non-Communicable Diseases, approximately 33% of adults in Oman suffer from hypertension, with the prevalence increasing to around 40% among individuals aged 35 years and older.

Similarly, metabolic disorders are becoming more widespread, as about one in seven adults (approximately 14%) experience high blood sugar levels, while more than 6,500 new diabetes cases are reported annually in the country .

In addition, dyslipidemia is another major concern, with around one-third of adults (about 33%) experiencing high cholesterol levels, and the prevalence rises to nearly 40% among people over 40 years of age.

The growing burden of obesity, hypertension, diabetes, and high cholesterol is significantly increasing demand for healthcare services, diagnostics, and chronic disease management in Oman. As these conditions continue to rise, healthcare infrastructure expansion and advanced treatment solutions will play a crucial role in supporting long-term market growth.

  1. Introduction
  2. Executive Summary
    1. Key Insights
    2. Key Findings (2020–2024)
    3. Market Outlook Snapshot (2025–2032F)
    4. Strategic Imperatives
  3. Macro Environment Analysis
    1.  Oman at a Glance
      1. Geographic Overview
      2. Political Structure
      3. Trade & Regional Alliances
      4. Others
    2. Demographic Profile (2020–2032F)
      1. Population Trends
      2. Age Structure
      3. Urban vs Rural Distribution
      4. Fertility Rate Trends
      5. Migration Trends
      6. Ethnic Composition
    3. Economic Profile (2020–2032F)
      1. GDP (Current & Constant USD)
      2. GDP by Sector
      3. Working Population & Labor Participation
      4. Per Capita Income & Purchasing Power
      5. Unemployment & Underemployment
      6. Inflation Rate & Healthcare Cost Impact
      7. Foreign Direct Investment Trends
    4. Oman PESTLE Analysis
  4.  Oman Healthcare Sector Analysis, 2026
    1. Healthcare System Overview
      1. Structure of Healthcare System
      2. Public vs Private Healthcare
      3. Governance & Regulatory Authorities
      4. Others
    2. Healthcare Ecosystem & Infrastructure (2020–2026)
      1. Healthcare Expenditure
        1. Healthcare Expenditure as % of GDP
        2. Per Capita Healthcare Expenditure
      2. Healthcare Facilities
        1. Number of Hospitals
        2. Number of Clinics
        3. Number of Pharmacies
        4. Number of Diagnostic Centres
        5. Public vs Private Distribution
        6. Bed Availability & Utilization
          1. Beds per 1,000 Population
          2. Beds Specialty
          3. Regional Disparities
      3. Healthcare Workforce
        1. Physicians per 1,000 Population
        2. Physicians by Specialty
        3. Nurses
        4. Dentists
        5. Allied Health Professionals
  5. Health Outcomes & Public Health Indicators (2020–2026)
    1. Life Expectancy (Male vs Female)
    2. Infant Mortality Rate
    3. Maternal Mortality Ratio
    4. Immunization Coverage Rates (Measles, DPT, HPV, COVID-19)
    5.  Overall Disease Burden Trends
  6. Healthcare Reforms & Large-Scale Projects (2020-2026)
    1. Government Reforms
    2. Public-Private Partnerships
    3. Infrastructure Expansion Projects
    4. Private Sector Investments
    5. Others
  7. Insurance Framework
    1. Public Health Insurance Programs
    2. Private Health Insurance Market
    3. Insurance Penetration & Coverage Gaps
    4. Payer Landscape
    5. Reimbursement Models (FFS, Bundled, Value-Based Care)
    6. Claims Management & Transparency Issues
    7. Out-of-Pocket Expenditure Trends (2020-2026)
  8. Regulatory Environment (Healthcare Sector)
    1. Market Authorisation for Pharmaceuticals
    2. Market Authorisation for Medical Devices
    3. Licensing for Manufacturing, Import & Export
    4. Clinical Trial Regulations
    5. Intellectual Property & Patent Protection
    6. Advertising, Labeling & Packaging Regulations
    7. Pharmacy & Hospital Licensing Rules
    8. Others
  9. Market Dynamics & Technology
    1. Healthcare Market Dynamics
      1. Growth Drivers
      2. Challenges & Barriers
      3. Emerging Opportunities
      4. Value Chain Analysis
    2. Healthcare Technology Trends
      1. Digital Health Maturity
      2. Telemedicine & Remote Monitoring
      3. Artificial Intelligence & Machine Learning
      4. Health Apps & Wearables
      5. Robotic Surgery
      6. EHR, Data Interoperability & Cybersecurity
      7. Others
  10. Epidemiology Profile (By Age & By Gender) (2020–2032F)
    1. Chronic Diseases
      1. Cardiovascular Diseases
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      2. Diabetes
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      3. Cancer
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      4. Chronic Respiratory Diseases
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      5. Chronic Kidney Disease
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
    2. Infectious Diseases
      1. Tuberculosis
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      2. HIV
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      3. Hepatitis
        1. Prevalence
        2. Incidence
        3. Mortality Rate
        4. Risk Factors
        5. Healthcare & Economic Burden
        6. Infrastructure Challenges
        7. Treatment Landscape
        8. Others
      4. Others
    3. Mental Health
      1. Prevalence of Mental Health Disorders
      2. Suicide Rates & Trends
      3. Urban-Rural & Gender Disparities
      4. Infrastructure Gaps
      5. Economic & Social Burden
  11.  Oman Healthcare System Stakeholders Analysis, 2026
    1.  Oman Pharmaceutical Market Outlook (2020–2030F)
      1. Market Size & Growth
        1. Market Size (USD Million), 2020-2030F
        2. Market by Key Segments
          1. Prescription vs OTC
          2. Generics vs Branded
          3. Therapeutic Category Distribution
      2. Manufacturing Landscape
      3. Distribution & Supply Chain
        1. Major Distributors
        2. Major Suppliers
      4. Major Local and Multinational Players
      5. Pharmaceutical sector (Top 5–10 companies, % market share)
      6. Imports & Exports (Value in USD Million) (2020-2026)
      7. Key Pharmaceutical Clusters (if there)
      8. Investments and R&D (2020-2026)
      9. Others
    2.  Oman Medical Devices Market Outlook (2020–2030F)
      1. Market Size & Growth
        1. Market Size (USD Million), 2020-2030F
        2. Market by Key Segments
          1. By Device Type
          2. By Risk Class
          3. By End-User
      2. Manufacturing Landscape
      3. Distribution & Supply Chain
        1. Distributors
        2. Supply Chain
      4. Major Local and Multinational Players
      5. Medical Devices Sector (Top 5–10 companies, % market share)
      6. Imports & Exports (Value in USD Million) (2020-2026)
      7. Key Medical Device Clusters (if there)
      8. Investments and R&D (2020-2026)
      9. Others
  12. Oman Strategic & Investments in Healthcare Outlook (2025-2032F)
    1. High-Growth Segments
    2. Foreign Investment Opportunities
    3. Government Incentives & Ease of Doing Business
    4. Risk Assessment & Mitigation
  13. Trade Associations & Industry Bodies
    1. Pharmaceutical Associations
    2. Medical Device Associations
    3. Healthcare Provider Associations
    4. Regulatory & Standards Bodies
  14. Healthcare Trade Fairs & Conferences (2024–2026)
    1. National Healthcare Exhibitions
    2. Medical Technology Events
    3. Pharmaceutical Conferences
    4. Regional Latin America Events Relevant to Oman
  15. Impact of Global Health Events
    1. COVID-19 Impact (2020–2022)
    2. Post-Pandemic Recovery
    3. Emergency Preparedness Evolution
  16. Strategic Recommendations
    1. Market Entry Strategy
    2. Partnership Models
    3. Pricing Strategy
    4. Regulatory Navigation
  17. Disclaimer


MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

Data Trangulation

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

Full Name*:

Company Name*:

Business Email*:

Country Name*:

Contact Number*:

Message:

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now
Inquire Before Buying
Customization Offered
  • Cross-segment Market Size & Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics & Share
  • Import Export & Production Analysis
Request Customization
Related Reports